Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories. It provides coverage across 51 assayed, research-use-only markers in a single vial, with markers spanning surface, intracellular, and leukocyte scatter populations, including CD200, TRBC1, cMPO, CD27, CD36, CD81, cCD79a, CD79b, cKappa, cLambda, and others.
June 2026—Baebies Finder Flu A and B/SARS-CoV-2 test received FDA 510(k) clearance and CLIA waiver on the Finder platform. The compact, automated PCR system delivers positive results in as few as 15 minutes and negative results in about 20 minutes.
May 2026—Streck released MDx-Chex for RLP, a ready-to-use, full-process molecular quality control designed for respiratory low-plex assay verification.
May 2026—The Diagnostic Medicine Consortium and Virchow Medical have formed a partnership aimed at expanding longitudinal, evidence-based cancer therapy to more patients.
May 2026—The FDA has approved Grifols’ Procleix Plasmodium assay for screening blood donors for malaria.
May 2026—The Food and Drug Administration has cleared the Qiagen QIAstat-Dx Gastrointestinal Panel 2 and QIAstat-Dx GI Panel 2 Mini B and Mini B&V for use on the QIAstat-Dx Rise automated syndromic testing system.
May 2026—Bruker’s microbiology and infection diagnostics division launched at ESCMID Global (April 17–21, Munich) the MyGenius Pro system in Europe.
May 2026—Sarstedt’s Tempus1800 sample transport system was awarded a Vizient innovative technology contract.
May 2026—City of Hope is implementing Quest Diagnostics’ Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial patients with solid tumor cancers to help guide disease management for breast, colorectal, ovarian, and prostate cancer.
May 2026—Labcorp launched the Labcorp Fentanyl Urine Visual test for the assessment of fentanyl exposure. The test detects norfentanyl, which can remain present in urine up to 48 hours after initial exposure.
